NCT05608252View on ClinicalTrials.gov

VS-6766+Abema+Fulv in Met HR+/HER- BC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Breast CancerHormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
DRUG

VS-6766

Taken Orally

DRUG

Abemaciclib

Taken Orally

DRUG

Fulvestrant

Administered by intramuscular injection

Trial Locations (3)

02114

WITHDRAWN

Massachusetts General Hospital Cancer Center, Boston

02115

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana Farber Cancer Institite, Boston

All Listed Sponsors
collaborator

Verastem, Inc.

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Adrienne G. Waks

OTHER